OBL-Pharm

OBL-Pharm, officially known as Pharmaceutical Enterprise Obolenskoye, is a leading Russian pharmaceutical company specializing in the development, production, and marketing of high-quality generic medications. Founded in 1994 and headquartered in the Moscow region, the company maintains a diverse portfolio of over 150 products across therapeutic areas such as gastroenterology, cardiology, and neurology. OBL-Pharm operates modern manufacturing facilities that are fully compliant with international GMP standards. In 2018, the company was acquired by a consortium including Sistema PJSFC and was subsequently merged into the Binnopharm Group, one of Russia's largest pharmaceutical holdings. Its flagship brands, including Venarus and Maxilac, hold significant market shares in their respective categories within the Russian Federation.